Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PI Forum Member Companies Maintain Interest in Drug Business
November 11, 2002
- TV Programs Should Be More Careful in Handling Healthcare Issues: Yamanouchi, Pfizer Seminar
November 11, 2002
- Roche Diagnostics: Accu-chek Compact Blood Glucose Meter
November 11, 2002
- FPMAJ Compiles Measures to Prevent Medical Accidents
November 11, 2002
- Life Science Summit Calls For Promotion of World's Leading R&D
November 11, 2002
- WORLD NEW IN BRIEF
November 11, 2002
- WEBSITE NEWS
November 11, 2002
- Researcher-led Clinical Trials on Anticancer Agents by NPO Introduced
November 11, 2002
- BUSINESS NEWS IN BRIEF
November 11, 2002
- CRCs Should Report All Events: SMO Seminar
November 11, 2002
- Fujisawa: Record-high Sales, Profits in 1st Half of FY2002 Marked
November 11, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 11, 2002
- Major Wholesalers' 1st-half Sales Unexpectedly Good
November 11, 2002
- Meiji Seika, Bayer to Comarket Bayclear Plus
November 11, 2002
- Freund: Sales Up 1.9%, Operating Profits Down 41.2%
November 11, 2002
- GSK, Block Drug Company (Japan) Integrated on November 1
November 11, 2002
- Health Minister Determines to Set Up Better Healthcare System
November 11, 2002
- Kuraya Sanseido Takes Over OTC Business from Heisei Yakuhin
November 11, 2002
- Korosho to Prepare Comprehensive GL for Clinical Trials
November 11, 2002
- Council to Issue Supplements QC Verification Seals
November 11, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…